The Profit Trap: How Private Equity Turned Autism Therapy into a Multi-Billion Dollar Industry at Children’s Expense

A groundbreaking investigation by The 74 has uncovered a startling reality behind the U.S. autism therapy sector: a massive, unchecked influx of private equity capital has transformed a clinical field into a profit-driven machine. Over the past six years, taxpayers have funneled $7 billion in Medicaid payments into Applied Behavior Analysis (ABA) services, yet the explosive growth of these clinics is increasingly tied to business practices that prioritize shareholder returns over the welfare of vulnerable children.

While political rhetoric has recently focused on individual cases of immigrant-led fraud, the systemic "financial boondoggle" identified by researchers suggests that the real scandal is not a matter of petty welfare theft, but a sophisticated, opaque model of institutionalized exploitation.

The Rise of the ABA Industrial Complex

Applied Behavior Analysis (ABA) has become the de facto standard of care for autistic children, largely driven by a well-intentioned but now-distorted advocacy movement that began in the mid-2000s. Originally championed by parents desperate for support, the "gold standard" therapy has ballooned into a $2 billion-per-year industry.

However, the rapid scaling of ABA has outpaced both the science and the oversight. Critics, including many autistic adults, argue that the therapy—which focuses on "extinguishing" neurodivergent traits—is often traumatizing and ineffective. Despite this, pediatricians continue to reflexively prescribe up to 40 hours of therapy per week for toddlers, a regimen experts describe as a "full-time job" that precludes necessary academic and social development.

A Chronology of Expansion and Capture

The transformation of autism therapy into a private equity asset class was not accidental; it was the result of a specific series of policy shifts and market opportunities:

• 2005–2007: Grassroots lobbying leads to the passage of "Ryan’s Law" in South Carolina, the first mandate for private insurers to cover ABA. This success, led by advocates like Lorri Unumb, provided the blueprint for state-by-state legislative victories.
• 2014: The Obama administration clarifies that the Affordable Care Act requires Medicaid to cover autism services, effectively opening the federal treasury to the burgeoning ABA industry.
• 2015–2019: Private equity firms recognize a lucrative opportunity in a fragmented market with steady, government-backed revenue streams. Buyout firms begin aggressive consolidation, acquiring hundreds of sites across the country.
• 2019–2024: The 74’s analysis of 275 million billing records shows Medicaid spending on the six most common ABA billing codes surging by 381%, from $400 million to nearly $2 billion annually.
• 2022–2025: Federal audits in both red and blue states reveal systemic billing irregularities, including charges for custodial care (bathing, feeding) and outright fraudulent claims for services never rendered.

Supporting Data: The Cost of Corporate Consolidation

The financial structure of private equity in healthcare is inherently designed to extract value, not to optimize clinical outcomes. Funds typically acquire companies through leveraged buyouts, loading the acquired clinics with debt. To service this debt and satisfy investors, the firms must prioritize high-volume, low-cost delivery.

The data is stark:

• Market Dominance: Of the 50 largest Medicaid-billing ABA providers, 23 are owned by private equity. These firms account for $2 billion in claims over the study period.
• The "Volume" Incentive: Former employees of major chains, such as the Blackstone-owned Center for Autism and Related Disorders (CARD), have reported pressure to prioritize younger children who can be enrolled in long-term, high-intensity, 40-hour-a-week programs.
• The Cost of Inaction: The $7 billion spent on ABA over six years dwarfs the $6 billion spent by the U.S. government over two decades on all research and quality-of-life programs under the Autism CARES Act. If these billions were redirected to public schools, every district in the country could afford to hire additional occupational and speech therapists—specialists in critical short supply.

The Human Toll: Beyond the Billing Codes

The most alarming findings concern the impact on children. Federal audits have documented children spending their formative years in standalone therapy centers, effectively isolated from peers and denied the educational rights guaranteed under federal law. In one case in Colorado, a child received therapy from age 2 to 16, with costs ballooning to $144,000 annually by the end of the term, without any independent review of the treatment’s necessity.

Research from the University of Wisconsin-Madison, Ohio State, and the University of Texas at Austin highlights a grim correlation: individuals who underwent ABA before age 18 were 30% more likely to require mental health hospitalizations compared to their peers. These findings echo the concerns of the autistic community, who note that ABA was developed by Ole Ivar Lovaas—the same researcher who pioneered gay conversion therapy—and that the methodology shares deep, problematic roots in eugenics and behaviorist control.

Official Responses and Corporate Defenses

The response from the industry has been one of compartmentalization. When confronted with allegations of abuse or billing fraud, private equity firms point to their portfolio companies, claiming they do not interfere in "clinical decisions."

In a statement to The 74, Blackstone claimed its management of CARD was hampered by a "perfect storm" of COVID-19 and labor shortages, maintaining that they worked to keep facilities open. Similarly, Centria Healthcare’s leadership has vigorously denied allegations of abuse and improper billing, emphasizing their commitment to providing care in underserved areas.

However, experts like Professor Rosemary Batt of Cornell University argue that the structure itself is the problem. "If a company gets caught in fraud, it’s just the cost of doing business," she notes. The legal architecture of private equity—where liability remains with the portfolio company—effectively shields parent firms and their investors from the consequences of systemic failure.

Implications: A Future at Risk

The current political climate has only added to the volatility. As the second Trump administration redirects funds and promotes controversial, unscientific "cures" for autism, disability advocates fear that the progress of the last few decades is being dismantled. The withholding of Medicaid funds from states like California and Minnesota as a political maneuver has already resulted in the loss of services for children with disabilities, creating a "dark past" scenario that many activists warned would happen.

For states attempting to regulate the industry, the path forward is fraught. Recent legislative attempts in Colorado to license ABA providers have been criticized by the disability community for "enshrining" a controversial practice rather than reforming it. By filling oversight boards with industry-aligned therapists, states risk institutionalizing the very practices that advocates say have failed children for generations.

Conclusion: A Call for Structural Reform

The evidence is clear: the ABA industry has become a vessel for private equity to siphon public funds under the guise of pediatric healthcare. While the industry touts "thousands of ethical providers," the structural incentives of the private equity model—debt, volume, and rapid exit strategies—are fundamentally incompatible with the slow, individualized, and compassionate care required by autistic children.

Unless there is a move toward joint liability for investment firms, strict oversight of clinical outcomes, and a shift in funding toward inclusive, school-based support, the "autism therapy crisis" will continue to be a tale of two realities: billions in profit for financial investors, and a lifetime of potential trauma for the children they were meant to serve. The question for policymakers is no longer whether there is fraud in the system, but whether they have the courage to dismantle a model that profits from the marginalization of the neurodivergent community.